Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.

Singh H, Bhandari R, Kaur IP.

Int J Pharm. 2013 Mar 25;446(1-2):106-11. doi: 10.1016/j.ijpharm.2013.02.012. Epub 2013 Feb 11.

PMID:
23410991
2.

Stability of rifampicin in dissolution medium in presence of isoniazid.

Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB.

Int J Pharm. 1999 Nov 10;190(1):109-23.

PMID:
10528103
3.

Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.

Wang Y, Liu H, Liu K, Sun J, He Z.

Pharm Dev Technol. 2013 Mar-Apr;18(2):401-6. doi: 10.3109/10837450.2012.659254. Epub 2012 Feb 18.

PMID:
22339279
4.

Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy.

G├╝rsoy A, Kut E, Ozkirimli S.

Int J Pharm. 2004 Mar 1;271(1-2):115-23.

PMID:
15129978
5.

Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.

Rajaram S, Vemuri VD, Natham R.

J Pharm Biomed Anal. 2014 Nov;100:103-8. doi: 10.1016/j.jpba.2014.07.027. Epub 2014 Aug 1.

PMID:
25151231
6.

Formulation and statistical optimization of a novel crosslinked polymeric anti-tuberculosis drug delivery system.

du Toit LC, Pillay V, Danckwerts MP, Penny C.

J Pharm Sci. 2008 Jun;97(6):2176-207.

PMID:
17879985
7.

Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design.

Chawla R, Jaiswal S, Mishra B.

Expert Opin Drug Deliv. 2014 Jan;11(1):31-43. doi: 10.1517/17425247.2013.807794. Epub 2013 Jun 27.

PMID:
23802585
8.

Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3.

Sankar R, Sharda N, Singh S.

Drug Dev Ind Pharm. 2003 Aug;29(7):733-8.

PMID:
12906330
9.

Entrapment of multiple anti-Tb drugs in microemulsion system: quantitative analysis, stability, and in vitro release studies.

Mehta SK, Kaur G, Bhasin KK.

J Pharm Sci. 2010 Apr;99(4):1896-911. doi: 10.1002/jps.21971.

PMID:
19894276
10.

Probing location of anti-TB drugs loaded in Brij 96 microemulsions using thermoanalytical and photophysical approach.

Kaur G, Mehta SK.

J Pharm Sci. 2014 Mar;103(3):937-44. doi: 10.1002/jps.23857. Epub 2014 Jan 14.

PMID:
24425102
11.

Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.

Mariappan TT, Singh S.

Int J Tuberc Lung Dis. 2003 Aug;7(8):797-803.

PMID:
12921157
12.

Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid.

Moretton MA, Hocht C, Taira C, Sosnik A.

Nanomedicine (Lond). 2014 Aug;9(11):1635-50. doi: 10.2217/nnm.13.154. Epub 2014 Jan 10.

PMID:
24410279
13.

Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.

Mehta SK, Jindal N.

Colloids Surf B Biointerfaces. 2013 Jan 1;101:434-41. doi: 10.1016/j.colsurfb.2012.07.006. Epub 2012 Jul 17.

PMID:
23010052
14.

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.

Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20.

15.

Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.

Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ.

Int J Pharm. 2001 Oct 9;228(1-2):53-67.

PMID:
11576768
16.

Study of the interaction between rifapentine and isoniazid under acid conditions.

Prasad B, Bhutani H, Singh S.

J Pharm Biomed Anal. 2006 Jun 16;41(4):1438-41. Epub 2006 Apr 18.

PMID:
16621412
17.

Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.

Seifart HI, Parkin DP, Donald PR.

Pediatr Infect Dis J. 1991 Nov;10(11):827-31.

PMID:
1749695
18.

In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.

Booysen LL, Kalombo L, Brooks E, Hansen R, Gilliland J, Gruppo V, Lungenhofer P, Semete-Makokotlela B, Swai HS, Kotze AF, Lenaerts A, du Plessis LH.

Int J Pharm. 2013 Feb 28;444(1-2):10-7. doi: 10.1016/j.ijpharm.2013.01.038. Epub 2013 Jan 26.

PMID:
23357255
19.

Alginate microspheres of isoniazid for oral sustained drug delivery.

Rastogi R, Sultana Y, Aqil M, Ali A, Kumar S, Chuttani K, Mishra AK.

Int J Pharm. 2007 Apr 4;334(1-2):71-7. Epub 2006 Oct 21.

PMID:
17113732
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk